 | This article may rely excessively on sources too closely associated with the subject , potentially preventing the article from being verifiable and neutral.(January 2025) |
Elizabeth A. Spencer is a British epidemiologist and researcher at the Centre for Evidence-Based Medicine (CEBM), University of Oxford, whose research focuses on systematic reviews, multimorbidity, and evidence synthesis. [1]
Spencer’s research spans areas of public health including living reviews, biomarkers, self-care in chronic conditions, and the impact of environmental exposures on health. [2] She has advanced strategies for managing multimorbidity. [3] [4] [5] [6] She has also enhanced methodologies in evidence synthesis, emphasising well-defined research questions, transparent methodologies, and comprehensive search strategies. [7]
At the Centre for Evidence-Based Medicine (CEBM), [8] Spencer is a major contributor to the Evidence-Based Multimorbidity Project. This initiative focuses on developing strategies for the early recognition, screening, and treatment of multimorbidity, aiming to reduce the burden of chronic conditions. [9] [10]
She has been involved in studies at CEBM including "Tamiflu as a Treatment for Influenza," evaluating its efficacy in combating influenza [11] and "Primodos and Congenital Malformations," which investigated the potential links between the hormonal pregnancy test and birth defects. [12] In addition, she has contributed to "Green Tea and Blood Pressure Effects," which examined the potential benefits of green tea consumption on blood pressure [13] and "Transmission of SARS-CoV-2," a study that focused on understanding the transmission dynamics of the virus, particularly among asymptomatic and pre-symptomatic individuals. [14]
Spencer was also involved in the launch of Open Evidence Reviews, an initiative by CEBM providing real-time updates on evidence related to COVID-19. This initiative addressed critical areas such as transmission dynamics, the effectiveness of public health interventions, and the role of PCR cycle thresholds in predicting infectiousness. [15] Her additional research suggests that PCR cycle threshold values may be crucial in predicting the infectiousness of asymptomatic or pre-symptomatic individuals with COVID-19. This study, part of a comprehensive review, highlights the importance of PCR testing in understanding transmission dynamics. [16]
She has researched the risks of hormone replacement therapy (HRT) using large-scale databases. She has also contributed to the Million Women Study, a landmark research project investigating the health of women aged 50 and over, with a focus on evaluating the risks and benefits of HRT and other health factors. [17] [18] [19] [20]
{{cite journal}}: |last5= has generic name (help)| Authority control databases: Academics |
|---|
